Clicky

BioInvent International AB(BINV)

Description: BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.


Keywords: Medicine Cancer Clinical Medicine Immunology Solid Tumors Immune System Antibodies Tumor Treatment Of Cancer Cancer Treatment Cancer Immunotherapy Oncolytic Virus Non Hodgkin Lymphoma Cutaneous T Cell Lymphoma

Home Page: www.bioinvent.com

The Gamma Building
Lund, 223 70
Sweden
Phone: 46 4 62 86 85 50


Officers

Name Title
Dr. Martin Welschof Ph.D. Pres & CEO
Mr. Stefan Ericsson M.B.A. Chief Financial Officer
Ms. Marie Moores M.Sc., R.G.N. Chief Operating Officer
Mr. Kristoffer Rudenholm Hansson Sr. VP of Technical Operations
Mr. Björn Frendéus Chief Scientific Officer
Ms. Cecilia Hofvander Sr. Director of Investor Relations
Dr. Andres McAllister Chief Medical Officer
Ms. Ingrid Teige Head of Preclinical Research
Ms. Sylvie Ryckebusch Chief Bus. Officer

Exchange: ST

Country: SE

Currency: Swedish krone (kr)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.4002
Price-to-Sales TTM: 7.2531
IPO Date:
Fiscal Year End: December
Full Time Employees: 93
Back to stocks